Moderna(MRNA) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna’s investigational individualized neoantigen therapy in combination with Merck’s Keytruda® for treatment of patient ...